Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesQualitative or Semiquantitative ImmunoassaysCPT cpt-86711-jcv-antibody-immunoassay-serum
    Ask Trek AI about this page

    CPT 86711: JCV (John Cunningham Virus) Antibody Immunoassay

    CPT code 86711 describes an immunoassay laboratory test performed by a lab analyst to detect antibodies to the John Cunningham virus (JCV) in patient serum; the service is a serologic antibody test typically provided as a clinical laboratory service in a hospital or independent diagnostic laboratory setting for evaluation of prior or ongoing JCV exposure.

    For related coverage guidance, see recent payer policy updates: Allergen Subcutaneous Immunotherapy (SCIT), Allergy Testing, Including Selected Blood, Serum and Cellular Testing and Toxicity Testing Corporate Medical Policy, Allergy and Sensitivity Tests of Uncertain Efficacy.

    Customize your policy alerts

    Sign up for cpt 86711 policy alerts

    Get alerted when payer policies referencing 86711 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Table of contents

    Progress1 / 7

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical & Coding Specifications

    Clinical Context

    A typical patient is a 45–65-year-old individual with multiple sclerosis (MS) or another demyelinating disorder who is being considered for or currently receiving natalizumab or another immunosuppressive therapy. Prior to initiating therapy and periodically during treatment, the clinician orders a serum immunoassay to detect antibodies against John Cunningham virus (JCV) to assess the patient’s risk of progressive multifocal leukoencephalopathy (PML). The clinical workflow: the ordering neurologist places the laboratory test for 86711 in the electronic health record with indication such as risk stratification for PML; phlebotomy collects a serum sample at an outpatient infusion center or ambulatory clinic; the specimen is sent to a hospital or reference laboratory; the lab analyst performs the immunoassay and reports a qualitative or quantitative JCV antibody result in the laboratory information system; the result is routed back to the treating neurologist who documents the finding and incorporates it into treatment planning or monitoring. Typical site of service is an outpatient laboratory, hospital laboratory, or ambulatory infusion center where blood is drawn and samples are processed by trained laboratory personnel.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    36415Collection of venous blood by venipuncturePerformed immediately before 86711 to obtain serum specimen for JCV antibody testing.
    88360Immunohistochemistry (IHC) staining, each antibody (if applicable for tissue-based JCV testing)Performed when JCV detection requires tissue-based immunostaining in biopsy specimens; not typical for serum assay but relevant in PML diagnosis workflow.
    86749Hepatitis C antibody, screen or confirmatory (example serologic assay category)Example of another serologic antibody test that may be ordered concurrently in immunosuppressed patients; illustrates laboratory serology workflow.
    99000Handling and/or conveyance of specimen (when used per payer rules)Used when additional specimen handling or special transport is required for 86711.
    84999Unlisted chemistry procedure (when specific assay lacks direct crosswalk for payer)Used only when the laboratory needs to report a JCV assay under an unlisted chemistry code for payer adjudication or novel methodologies.

    Related Modifiers

    7 rows

    ModifierDescriptionWhen to Use
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    90Modifier ‑90 (Reference/Outside Laboratory) indicates that a laboratory test was performed by an entity other than the treating or reporting provider. The American Medical Association defines…- Use CPT modifier -90 when a laboratory test is performed by an outside/reference laboratory (an entity other than the treating or reporting physician or qualified professional) and the claim needs…
    91Modifier 91 — “Repeat Clinical Diagnostic Laboratory Test” — is appended when the exact same CPT laboratory test is performed more than once for the same patient on the same day because serial,…- Use modifier 91 when the exact same CPT laboratory test is performed more than once on the same patient on the same date because serial or repeated testing is medically necessary to monitor…
    59Modifier 59 indicates a distinct procedural service when two procedures that are not normally billed together are clinically and procedurally separate. The CPT definition (as reiterated by CMS)…- Use modifier -59 to report a distinct procedural service when documentation supports that the procedure reported is not normally billed together with another service on the same day because of a…
    76Modifier -76, Repeat Procedure or Service by Same Physician or Other Qualified Health Care Professional, is appended when the same provider performs an identical, medically necessary procedure or…- Use modifier -76 when the same physician or other qualified health care professional performs an identical procedure or service a second (or subsequent) time on the same date of service and the…
    77Modifier 77 indicates that a previously performed procedure or service was legitimately repeated by a different physician or other qualified health care professional. The AMA’s CPT definition…- Use modifier 77 when a basic procedure or service already performed is repeated by a different physician or other qualified health care professional (for example, a second provider independently…
    53Modifier 53 (Discontinued Procedure) signals that a surgical or diagnostic service was begun by the physician but terminated because of extenuating circumstances that threatened the patient’s…- Use modifier -53 when a physician/qualified healthcare professional has started a surgical or diagnostic procedure (e.g., anesthesia administered, incision or scope insertion) and then discontinues…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    207RG0300X
    207RH0000X
    207L00000X
    207K00000X
    2084P0800X
    246ZS0410X
    163WA0400X
    364SP1700X

    Related ICD-10-CM Codes

    24 rows

    ICD-10-CM CodeDescription
    A81.9Atypical virus infection of central nervous system, unspecified
    B20Human immunodeficiency virus [HIV] disease
    B25.9Cytomegaloviral disease, unspecified
    C71.9Malignant neoplasm of brain, unspecified
    D61.9Aplastic anemia, unspecified
    D89.9Disorder involving the immune mechanism, unspecified
    F32.9Major depressive disorder, single episode, unspecified
    F33.9Major depressive disorder, recurrent, unspecified
    G04.81Other encephalitis and encephalomyelitis
    G04.90Encephalitis and encephalomyelitis, unspecified

    Showing 1–10 of 24

    Related Payer Policy Updates

    Specialty: Allergy/Clinical Immunology1 / 3

    10 rows

    PolicyPayerEffective Date
    Allergen Subcutaneous Immunotherapy (SCIT)Providence Health Plan2026-11-01
    Allergy Testing, Including Selected Blood, Serum and Cellular Testing and Toxicity Testing Corporate Medical Policybcbsvermont2026-11-01
    Allergy and Sensitivity Tests of Uncertain Efficacyregence2026-10-01
    Allergy Testing and InjectionsUnitedHealthcare2026-10-01
    Allergy TestingProvidence Health Plan2026-10-01
    Diagnosis of Idiopathic Environmental IntoleranceOscar Health2026-10-01
    Allergen Testingblue cross blue shield - louisiana2026-09-15
    Allergen TestingBlue Cross Blue Shield - New Mexico2026-09-04
    Allergen Immunotherapymarylandphysicianscarempc2026-09-01
    ALLERGY TESTING / IMMUNOTHERAPYpriority_health_medicare2026-09-01

    Related Codes

    86803-QUALITATIVE-OR-SEMIQUANTITATIVE-IMMUNOASSAYS-HEPATITIS-C

    CPT 86803: Hepatitis C Antibody Immunoassay in Serum

    CPT-86000-FEBRILE-AGGLUTININS-SEROLOGIC-TEST

    CPT 86000: Febrile Agglutinins (Serologic Agglutination) Test

    CPT-86001-ALLERGEN-SPECIFIC-IGG-LABORATORY-TEST

    CPT 86001: Allergen-Specific IgG Assay, Technical Component

    CPT-86003-ALLERGEN-SPECIFIC-IGE-ASSAY-TECHNICAL

    CPT 86003: Allergen‑Specific IgE Assay Using Crude Allergen Extract

    CPT-86005-MULTI-ALLERGEN-IGE-SCREENING-QUALITATIVE

    CPT 86005: Multi-Allergen Allergen-Specific IgE Screening

    CPT-86008-ALLERGEN-COMPONENT-SPECIFIC-IGE-ASSAY

    CPT 86008: Allergen Component–Specific IgE Assay

    CPT-86015-ANTI-ACTIN-SMOOTH-MUSCLE-ANTIBODY-ASMA

    CPT 86015: Actin (Smooth Muscle) Antibody (ASMA) Immunoassay

    CPT-86021-LEUKOCYTE-ANTIBODY-IDENTIFICATION-LAB-TECHNICAL

    CPT 86021: Leukocyte Antibody Identification Laboratory Test

    CPT-86022-PLATELET-ANTIBODY-IDENTIFICATION-TECHNICAL-TEST

    CPT 86022: Platelet Antibody Detection and Identification

    CPT-86023-PLATELET-ASSOCIATED-IMMUNOGLOBULIN-DETECTION

    CPT 86023: Platelet-Associated Immunoglobulin Assay

    Showing 1–10 of 199

    • More pages

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.